IBRX

ImmunityBio, Inc.

6.45 USD
+0.09 (+1.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ImmunityBio, Inc. stock is up 10.63% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 9 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Jun 15:59 18 Oct, 2024 5.50 CALL 150 335
26 Jun 14:41 17 Jan, 2025 7.50 CALL 204 8933
26 Jun 19:41 19 Jul, 2024 10.00 PUT 2000 11381
27 Jun 16:28 17 Jan, 2025 7.50 CALL 220 8783
28 Jun 14:09 17 Jan, 2025 7.50 CALL 220 9013
28 Jun 15:59 17 Jan, 2025 7.50 PUT 100 1397
28 Jun 19:48 16 Jan, 2026 10.00 CALL 200 5315
01 Jul 18:54 17 Jan, 2025 7.50 CALL 192 9004
12 Jul 13:52 30 Aug, 2024 5.50 PUT 3000 5000
12 Jul 19:02 18 Oct, 2024 10.00 CALL 700 6636

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.